Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 9th Preview)
-
US regulators lock in FDA leadership for drug and biologics oversight
The Trump administration moved three acting FDA center heads into permanent leadership roles, stabilizing key review functions across drugs and biologics. The FDA named Michael Davis to lead CDER, Karim Mikhail to lead CBER, and Bret Koplow to lead the Center for Tobacco Products, following prior acting assignments. The change also included the FDA’s first Deputy Commissioner for Technology and Artificial Intelligence, Jared Seehafer, signaling continued agency focus on AI-enabled review workflows as leadership roles consolidate. The appointments arrive ahead of a commissioner confirmation pipeline that remains underway. For biotech, the immediate impact is continuity of scientific and regulatory decision-making in product areas governed by CDER and CBER, including oncology small molecules, biologics, vaccines, gene therapies, and advanced modalities. The AI deputy role adds a structural emphasis on how evidence packages and review operations may be processed going forward.
-
FDA accelerated approval returns AstraZeneca’s oral SERD to first-line use
The FDA granted accelerated approval to AstraZeneca’s oral SERD camizestrant (Etcamah/camizestrant), overturning a prior advisory committee vote that had gone against the drug for first-line breast cancer. The decision covers patients with HR+/HER2- advanced breast cancer harboring ESR1 mutations detected during aromatase inhibitor and CDK4/6 inhibitor therapy. The approval also comes alongside Guardant Health’s Guardant360 companion diagnostic to identify ESR1 mutations. In SERENA-6, the company reported progression-free survival results meeting the primary endpoint, while the earlier panel raised concerns about the design and the randomized treatment switch based on mutation detection timing. Biotech implications are immediate for SERD developers and companion diagnostic strategies: the FDA’s approval effectively validates ESR1 mutation testing earlier in the treatment course and keeps a competitive oral SERD option in play for HR+/HER2- settings. It also increases the importance of evidence design around switch criteria and maturity of overall survival data.
-
Roivant’s mosliciguat posts Phase 2 win in interstitial lung disease
Roivant reported Phase 2 success for mosliciguat, an inhaled therapy for interstitial lung disease, meeting key endpoints in a 16-week study. The company said mosliciguat achieved a statistically significant 56% placebo-adjusted reduction in pulmonary vascular resistance, alongside improvements in six-minute walk distance and NT-proBNP. The readout follows Roivant’s acquisition of mosliciguat from Bayer, and it is positioned as a potential growth driver for the company as additional clinical milestones approach. A positive mid-stage outcome can strengthen near-term partnering optionality and improve financing leverage for later development steps. For biotech, the impact centers on inhaled vasculature-targeting strategies and the competitive landscape of pulmonary hypertension and related cardiopulmonary indications. Mosliciguat’s progression suggests more momentum for inhaled small molecules targeting cardiopulmonary physiology rather than systemic agents.
-
Novartis stumbles as pelacarsen fails cardiovascular Phase 3 outcomes
Novartis’ antisense therapy pelacarsen failed to demonstrate clinical benefit in its Phase 3 cardiovascular outcomes study, according to the company’s readout. Although prior work showed substantial lipoprotein(a) lowering, the Lp(a)HORIZON trial did not hit its primary endpoint spanning cardiovascular death, non-fatal MI, non-fatal stroke, and urgent revascularization requiring hospitalization. Analysts described the result as a setback for Lp(a)-lowering programs where biomarker reductions had previously driven optimism. The outcome increases the proof burden for other dedicated Lp(a) therapies in late-stage development, including siRNA approaches from Eli Lilly and Amgen. The broader biotech effect is on cardiovascular target validation: pelacarsen’s failure underscores that strong biomarker modulation does not guarantee event reduction, and it may influence partner diligence, trial design scrutiny, and near-term risk tolerance for Lp(a) lowering assets.
-
Moonwalk wins Series B funding to take adipose-targeted RNAi obesity program to humans
Moonwalk Biosciences raised $70 million in a Series B round to advance MW-101, its adipose-targeted RNAi obesity candidate, into clinical testing. The company plans to complete IND-enabling studies and initiate first-in-human studies in late 2027, with proceeds also funding additional tissue-targeted siRNA programs. The round was co-led by Alpha Wave Ventures and YK Bioventures and included Eli Lilly and other investors. Moonwalk’s approach targets adipose tissue to modulate energy homeostasis and fat-cell biology with an RNAi mechanism designed to preserve lean mass while reducing fat mass in preclinical models. For the obesity pipeline, the financing supports a differentiated alternative to incretin-centered regimens and reinforces investor appetite for genetic medicine delivery formats. If clinical safety and target engagement translate, adipose-directed RNAi could add a new competitive lane beyond GLP-1 and related metabolic drugs.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.